Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2001:1:8.
doi: 10.1186/1471-230x-1-8. Epub 2001 Aug 29.

Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis

L G Quallich  1 , J Greenson, H M Haftel, R J Fontana
Affiliations
Case Reports

Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis

L G Quallich et al. BMC Gastroenterol. 2001.

Abstract

Background: Sulfasalazine is a widely used anti-inflammatory agent in the treatment of inflammatory bowel disease and several rheumatological disorders. Although as many as 20% of treated patients may experience reversible, dose-dependent side effects, less frequent but potentially severe, systemic reactions have also been reported.

Case presentation: A severe systemic reaction to sulfasalazine developed in a 21-year old female with rheumatoid arthritis characterized by eosinophilia, granulomatous enteritis and myelotoxicity, cholestatic hepatitis, and seizures. The clinical course and management of this patient are presented as well as a review of the incidence and outcome of severe systemic reactions to sulfasalazine.

Conclusions: Granulomatous myelotoxicity and enteritis developed in a 21 year old female within 3 weeks of initiating sulfasalazine for rheumatoid arthritis. Following a short course of corticosteroids, the patient had resolution of her cholestatic hepatitis, rash, eosinophilia, and gastrointestinal symptoms with no residual manifestations at 7 months follow-up. Although severe reactions to sulfasalazine are rare and unpredictable, practicing physicians should be aware of unusual clinical presentations of toxicity when prescribing sulfasalazine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: Medium-power photomicrograph of the colon showing a small epithelioid granuloma (arrow) (Hematoxylin and eosin stain. B: Low-power photomicrograph of bone marrow showing a hypercellular marrow with an epithelioid granuloma (arrow) (Hematoxylin and eosin stain).
Figure 2
Figure 2
Liver biochemical profile. The patient had a normal serum alkaline phosphatase and bilirubin level 14 days prior to presentation. The marked intrahepatic cholestasis did not improve until initiation of steroids on day #14. At post-discharge follow-up on day #40, both the serum alkaline phosphatase and bilirubin had normalized. * = Upper limit of normal
See this image and copyright information in PMC

References

    1. Peppercorn MA. Sulphasalazine pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med. 1984;3:377–386. - PubMed
    1. Das KM. Sulphasalazine therapy in inflammatory bowel disease. Gastroenterol Clin North Amer. 1989;18:1–20. - PubMed
    1. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulfasalazine in the treatment of ulcerative colitis. Gut. 1964;5:437–432. - PMC - PubMed
    1. Dougados M, Van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of sponyloarthropathy: a randomized, multi-center, double-blinded, placebo-controlled study. Arthritis Rheum. 1995;38:618–627. - PubMed
    1. Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. Arthritis Rheum. 1986;29:1427–1434. - PubMed

Publication types

MeSH terms